Collaboration and other revenue associated with prior period transfers of intellectual property — Revenue
Eli Lilly Collaboration and other revenue associated with prior period transfers of intellectual property — Revenue increased by 2.6% to $19.80B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 55.5%, from $12.73B to $19.80B. Over 2 years (FY 2020 to FY 2025), Collaboration and other revenue associated with prior period transfers of intellectual property — Revenue shows an upward trend with a 121.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase suggests successful licensing strategies or strong market performance of licensed products by partners, while a decrease may indicate patent expirations or declining demand for licensed technologies.
Detailed definition
This metric represents the revenue generated from licensing intellectual property, patents, or drug formulations to thir...
Peer comparison
Common in large pharmaceutical firms that maintain diverse portfolios of intellectual property and strategic licensing agreements with regional or specialty partners.
lly_segment_royalty_revenuesHistorical Data
| Q2 '21 | Q2 '21 | Q3 '21 | Q3 '21 | Q4 '21 | Q4 '21 | Q1 '22 | Q1 '22 | Q2 '22 | Q2 '22 | Q3 '22 | Q3 '22 | Q4 '22 | Q4 '22 | Q1 '23 | Q1 '23 | Q2 '23 | Q2 '23 | Q3 '23 | Q3 '23 | Q4 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.74B | $31.00M | $6.77B | $62.10M | $8.00B | $38.90M | $7.81B | $53.20M | $6.49B | $34.40M | $6.94B | $43.30M | $7.30B | $32.50M | $6.96B | $25.10M | $8.31B | $30.30M | $9.50B | $31.30M | $9.35B | $104.90M | $8.77B | $11.30B | $11.44B | $13.53B | $12.73B | $15.56B | $17.60B | $19.29B | $19.80B |
| QoQ Change | — | -99.5% | >999% | -99.1% | >999% | -99.5% | >999% | -99.3% | >999% | -99.5% | >999% | -99.4% | >999% | -99.6% | >999% | -99.6% | >999% | -99.6% | >999% | -99.7% | >999% | -98.9% | >999% | +28.9% | +1.2% | +18.3% | -5.9% | +22.2% | +13.1% | +9.6% | +2.6% |
| YoY Change | — | — | — | — | — | — | — | — | -3.7% | -99.5% | +2.5% | -99.4% | -8.7% | -99.6% | -10.9% | -99.7% | +28.1% | -99.5% | +36.8% | -99.5% | +28.1% | -98.6% | +26.0% | +36.0% | +20.4% | +44.7% | +45.2% | +37.6% | +53.9% | +42.6% | +55.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's collaboration and other revenue associated with prior period transfers of intellectual property — revenue?
- Eli Lilly (LLY) reported collaboration and other revenue associated with prior period transfers of intellectual property — revenue of $19.80B in Q1 2026.
- How has Eli Lilly's collaboration and other revenue associated with prior period transfers of intellectual property — revenue changed year-over-year?
- Eli Lilly's collaboration and other revenue associated with prior period transfers of intellectual property — revenue increased by 55.5% year-over-year, from $12.73B to $19.80B.
- What is the long-term trend for Eli Lilly's collaboration and other revenue associated with prior period transfers of intellectual property — revenue?
- Over 2 years (2020 to 2025), Eli Lilly's collaboration and other revenue associated with prior period transfers of intellectual property — revenue has grown at a 121.8% compound annual growth rate (CAGR), from $13.25B to $65.18B.
- What does collaboration and other revenue associated with prior period transfers of intellectual property — revenue mean?
- Revenue earned by licensing the company's intellectual property and drug patents to other companies.